Atherosclerosis plus最新文献

英文中文

HEART UK 2023 Moderated Posters HEART UK 2023 主持人海报

IF 1.6

Atherosclerosis plus

Pub Date : 2023-12-01 DOI: 10.1016/j.athplu.2023.07.010

引用次数: 0

HEART UK 2023 Oral Presentations HEART UK 2023 口头报告

IF 1.6

Atherosclerosis plus

Pub Date : 2023-12-01 DOI: 10.1016/j.athplu.2023.07.022

引用次数: 0

How many individuals with Familial Hypercholesterolaemia (FH) need to be identified to achieve the NHS 2019 Long Term Plan ambition? 要实现国家医疗服务体系 2019 年长期计划的目标，需要确定多少名家族性高胆固醇血症 (FH) 患者？

IF 1.6

Atherosclerosis plus

Pub Date : 2023-12-01 DOI: 10.1016/j.athplu.2023.07.016

S.E. Humphries , J.Gratton , K. Haralambos , M. Futema

引用次数: 0

How many FH genetic tests were performed by the UK Genetic Laboratory Hubs in 2022? 2022 年，英国基因实验室中心进行了多少次 FH 基因检测？

IF 1.6

Atherosclerosis plus

Pub Date : 2023-12-01 DOI: 10.1016/j.athplu.2023.07.005

S.E. Humphries , R. Challis , K. Downes , E. Howard , T. Legerton , C. Macanulty , S. Morgan , A. O’Rouke , D. O’Sullivan , A. Taylor-Beadling , E. Thompson , E. Watson , G. Norbury

引用次数: 0

Familial Chylomicronaemia Syndrome (FCS) Compared to Multifactorial Chylomicronaemia Syndrome (MCS) – Lessons learnt from United Kingdom FCS Registry 家族性乳糜微粒血症综合征（FCS）与多因素乳糜微粒血症综合征（MCS）的比较--从英国 FCS 登记中汲取的经验教训

IF 1.6

Atherosclerosis plus

Pub Date : 2023-12-01 DOI: 10.1016/j.athplu.2023.07.018

B. Bashir , S. Kwok , A.S. Wierzbicki , A. Jones , C. Dawson , P. Downie , F. Jenkinson , P. Gupta , M. Mansfield , R. Kumari , D. Datta , H. Delaney , Y. Teoh , M. Williams , N. Forrester , D. O’Sullivan , Z. Miedzybrodzka , J. Payne , H. Soran

引用次数: 0

Familial Chylomicronaemia Syndrome (FCS) Score Validation in United Kingdom FCS Registry: Can Additional Variables Improve the FCS Score Performance? 家族性乳糜微粒血症综合征（FCS）评分在英国 FCS 登记处的验证：附加变量能否提高 FCS 评分的性能？

IF 1.6

Atherosclerosis plus

Pub Date : 2023-12-01 DOI: 10.1016/j.athplu.2023.07.004

B. Bashir , S. Kwok , A.S. Wierzbicki , A. Jones , C. Dawson , P. Downie , F. Jenkinson , P. Gupta , H. Dealeny , M. Mansfield , R. Kumari , D. Datta , Y. Teoh , M. Williams , N. Forrester , D. O’Sullivan , Z. Miedzybrodzka , A. Gallo , P. Moulin , J. Payne , H. Soran

引用次数: 0

ITGB2 is a central hub-gene associated with inflammation and early fibro-atheroma development in a swine model of atherosclerosis 在猪动脉粥样硬化模型中，ITGB2是一个与炎症和早期纤维动脉粥样硬化发展相关的中心枢纽基因

IF 1.6

Atherosclerosis plus

Pub Date : 2023-11-15 DOI: 10.1016/j.athplu.2023.11.001

Hadjer Namous , Maria Giuseppina Strillacci , Camila Urbano Braz , Dhanu Shanmuganayagam , Christian Krueger , Athanasios Peppas , William C. Soffregen , Jess Reed , Juan F. Granada , Hasan Khatib

Background and aim

The complex dynamic interplay between different biological pathways involved in atherosclerosis development has rendered the identification of specific therapeutic targets a challenging quest. We aimed to identify specific genes and mechanistic pathways associated with the early development of fibro-atheromas in a swine model of atherosclerosis.

Methods

The Wisconsin Miniature Swine™ model of Familial Hypercholesterolemia (WMS-FH, n = 11) and genetically related WMS controls (WMS-N, n = 11) were used. The infrarenal aorta was harvested from both groups for histopathologic and transcriptomic profiling at 12 months. Bioinformatic analysis was performed to identify hub genes and pathways central to disease pathophysiology. The expression of ITGB2, the top ranked hub gene, was manipulated in cell culture and the expression of interconnected genes was tested.

Results

Fibro-atheromatous lesions were documented in all WMS-FH aortic tissues and displayed internal elastic lamina (IEL) disruption, significant reduction of myofibroblast presence and disorganized collagen deposition. No fibro-atheromas were observed in the control group. A total of 266 differentially expressed genes (DEGs) were upregulated in WMS-FH aortic tissues, while 29 genes were downregulated. Top identified hub genes included ITGB2, C1QA, LCP2, SPI1, CSF1R, C5AR1, CTSS, MPEG1, C1QC, and CSF2RB. Overexpression of ITGB2 resulted in elevated expression of other interconnected genes expressed in porcine endothelial cells.

Conclusion

In a swine translational model of atherosclerosis, transcriptomic analysis identified ITGB2 as a central hub gene associated inflammation and early fibroatheroma development making it a potential therapeutic target at this stage of disease.

背景与目的动脉粥样硬化发展过程中不同生物学途径之间复杂的动态相互作用使得确定特定的治疗靶点成为一项具有挑战性的任务。我们的目的是在猪动脉粥样硬化模型中确定与纤维动脉粥样硬化早期发展相关的特定基因和机制途径。方法采用威斯康辛小型猪™家族性高胆固醇血症模型(WMS- fh, n = 11)和遗传相关的WMS对照组(WMS- n, n = 11)。12个月时采集两组的肾下主动脉进行组织病理学和转录组学分析。进行生物信息学分析以确定疾病病理生理的中心基因和通路。在细胞培养中操纵排在首位的枢纽基因ITGB2的表达，并检测互联基因的表达。结果所有WMS-FH主动脉组织均出现纤维粥样硬化病变，并表现为内部弹性层(IEL)破坏，肌成纤维细胞存在明显减少，胶原沉积紊乱。对照组未见纤维动脉粥样硬化。在WMS-FH主动脉组织中，共有266个差异表达基因(DEGs)上调，29个基因下调。最高鉴定的枢纽基因包括ITGB2、C1QA、LCP2、SPI1、CSF1R、C5AR1、CTSS、MPEG1、C1QC和CSF2RB。ITGB2的过表达导致猪内皮细胞中其他相关基因的表达升高。在猪动脉粥样硬化的翻译模型中，转录组学分析发现ITGB2是炎症和早期纤维动脉粥样硬化发展相关的中心枢纽基因，使其成为该疾病阶段的潜在治疗靶点。

{"title":"ITGB2 is a central hub-gene associated with inflammation and early fibro-atheroma development in a swine model of atherosclerosis","authors":"Hadjer Namous , Maria Giuseppina Strillacci , Camila Urbano Braz , Dhanu Shanmuganayagam , Christian Krueger , Athanasios Peppas , William C. Soffregen , Jess Reed , Juan F. Granada , Hasan Khatib","doi":"10.1016/j.athplu.2023.11.001","DOIUrl":"https://doi.org/10.1016/j.athplu.2023.11.001","url":null,"abstract":"<div><h3>Background and aim</h3><p>The complex dynamic interplay between different biological pathways involved in atherosclerosis development has rendered the identification of specific therapeutic targets a challenging quest. We aimed to identify specific genes and mechanistic pathways associated with the early development of fibro-atheromas in a swine model of atherosclerosis.</p></div><div><h3>Methods</h3><p>The Wisconsin Miniature Swine™ model of Familial Hypercholesterolemia (WMS-FH, n = 11) and genetically related WMS controls (WMS-N, n = 11) were used. The infrarenal aorta was harvested from both groups for histopathologic and transcriptomic profiling at 12 months. Bioinformatic analysis was performed to identify hub genes and pathways central to disease pathophysiology. The expression of ITGB2, the top ranked hub gene, was manipulated in cell culture and the expression of interconnected genes was tested.</p></div><div><h3>Results</h3><p>Fibro-atheromatous lesions were documented in all WMS-FH aortic tissues and displayed internal elastic lamina (IEL) disruption, significant reduction of myofibroblast presence and disorganized collagen deposition. No fibro-atheromas were observed in the control group. A total of 266 differentially expressed genes (DEGs) were upregulated in WMS-FH aortic tissues, while 29 genes were downregulated. Top identified hub genes included ITGB2, C1QA, LCP2, SPI1, CSF1R, C5AR1, CTSS, MPEG1, C1QC, and CSF2RB. Overexpression of ITGB2 resulted in elevated expression of other interconnected genes expressed in porcine endothelial cells.</p></div><div><h3>Conclusion</h3><p>In a swine translational model of atherosclerosis, transcriptomic analysis identified ITGB2 as a central hub gene associated inflammation and early fibroatheroma development making it a potential therapeutic target at this stage of disease.</p></div>","PeriodicalId":72324,"journal":{"name":"Atherosclerosis plus","volume":null,"pages":null},"PeriodicalIF":1.6,"publicationDate":"2023-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667089523000433/pdfft?md5=320bdbb10453fa6086111075d9285e05&pid=1-s2.0-S2667089523000433-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138437068","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Fetuin-A levels in association with calcific aortic valve disease: A meta-analysis 胎儿素A水平与钙化主动脉瓣疾病相关:一项荟萃分析

IF 1.6

Atherosclerosis plus

Pub Date : 2023-09-26 DOI: 10.1016/j.athplu.2023.09.004

Muhammad Omar Larik

Background and aims

Calcific aortic valve disease (CAVD) is a common valvular disease, prevalent particularly within the older age groups. The potential use of biomarkers in diagnosing and assessing the severity of CAVD, in supplementation with imaging techniques, has recently gained momentum within the field of cardiovascular medicine. Therefore, a meta-analysis was performed that assessed the association between the fetuin-A levels, and the presence of CAVD.

Methods

PubMed and Cochrane were searched from inception to April 2023. Risk of bias was assessed using the Newcastle-Ottawa scale for cohort studies.

Results

This analysis includes a total of 3,280 patients with CAVD, and 7,505 patients as control, resulting in the pooling of 10,785 patients in this meta-analysis. It was observed that the circulating levels of fetuin-A were significantly lowered in patients with CAVD (SMD: -0.20; 95% CI: -0.39, -0.02; P = 0.03). Moreover, the analysis revealed that fetuin-A levels had no significant association with CAVD in patients suffering from kidney disease (SMD: 0.20; 95% CI: -0.46, 0.85; P = 0.56).

Conclusion

While initial results demonstrate the potential effectiveness, further research is essential in order to arrive at a robust conclusion regarding the use of fetuin-A as a diagnostic biomarker for calcific aortic valve disease.

背景和目的钙化性主动脉瓣病（CAVD）是一种常见的瓣膜病，尤其在老年人群中流行。生物标志物在诊断和评估CAVD严重程度方面的潜在用途，加上成像技术，最近在心血管医学领域获得了发展势头。因此，进行了一项荟萃分析，评估胎球蛋白-a水平与CAVD存在之间的关系。方法从开始到2023年4月检索PubMed和Cochrane。使用纽卡斯尔-渥太华量表进行队列研究，评估偏倚风险。结果该分析共包括3280名CAVD患者，7505名患者作为对照，结果在该荟萃分析中汇集了10785名患者。CAVD患者血清胎球蛋白-A水平显著降低（SMD:-0.20；95%CI:-0.39，-0.02；P=0.03），分析显示，在肾病患者中，胎球蛋白-A水平与CAVD没有显著相关性（SMD:0.20；95%CI:0.460.85；P=0.56），为了得出关于使用胎蛋白-a作为钙化性主动脉瓣疾病的诊断生物标志物的有力结论，进一步的研究是至关重要的。

{"title":"Fetuin-A levels in association with calcific aortic valve disease: A meta-analysis","authors":"Muhammad Omar Larik","doi":"10.1016/j.athplu.2023.09.004","DOIUrl":"10.1016/j.athplu.2023.09.004","url":null,"abstract":"<div><h3>Background and aims</h3><p>Calcific aortic valve disease (CAVD) is a common valvular disease, prevalent particularly within the older age groups. The potential use of biomarkers in diagnosing and assessing the severity of CAVD, in supplementation with imaging techniques, has recently gained momentum within the field of cardiovascular medicine. Therefore, a meta-analysis was performed that assessed the association between the fetuin-A levels, and the presence of CAVD.</p></div><div><h3>Methods</h3><p>PubMed and Cochrane were searched from inception to April 2023. Risk of bias was assessed using the Newcastle-Ottawa scale for cohort studies.</p></div><div><h3>Results</h3><p>This analysis includes a total of 3,280 patients with CAVD, and 7,505 patients as control, resulting in the pooling of 10,785 patients in this meta-analysis. It was observed that the circulating levels of fetuin-A were significantly lowered in patients with CAVD (SMD: -0.20; 95% CI: -0.39, -0.02; P = 0.03). Moreover, the analysis revealed that fetuin-A levels had no significant association with CAVD in patients suffering from kidney disease (SMD: 0.20; 95% CI: -0.46, 0.85; P = 0.56).</p></div><div><h3>Conclusion</h3><p>While initial results demonstrate the potential effectiveness, further research is essential in order to arrive at a robust conclusion regarding the use of fetuin-A as a diagnostic biomarker for calcific aortic valve disease.</p></div>","PeriodicalId":72324,"journal":{"name":"Atherosclerosis plus","volume":null,"pages":null},"PeriodicalIF":1.6,"publicationDate":"2023-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10562872/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41221650","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The LIPL study: Postprandial lipid profile, inflammation, and platelet activity in patients with chronic coronary syndrome LIPL研究：慢性冠状动脉综合征患者餐后血脂、炎症和血小板活性。

IF 1.6

Atherosclerosis plus

Pub Date : 2023-09-21 DOI: 10.1016/j.athplu.2023.09.002

Edita Pogran , Paul M. Haller , Claudia Wegberger , Maximilian Tscharre , Irena Vujasin , Christoph C. Kaufmann , Petra Dick , Bernhard Jäger , Johann Wojta , Kurt Huber

Background and aims

It is suggested that the changes in atherosclerosis happen mainly under the influence of non-fasting lipids. To date, the studies in the postprandial state were primarily performed on healthy subjects. This exploratory, cross-sectional study investigates the change in lipid profile, inflammation, and platelet activation in patients with different cardiovascular risk profiles in the postprandial state.

Methods

The studied population consists of 66 patients with different cardiovascular risks: patients with a history of the chronic coronary syndrome (CCS) and diabetes mellitus type 2 (DM2) (n = 20), CCS without DM2 (n = 25), and a healthy control group (n = 21). Lipid variables and markers of platelet function and inflammation were assessed during the fasting state and three and 5 h after a standardized fat meal using a standardized oral fat tolerance test (OFTT), a milkshake with 90 g of fat.

Results

Patients with CCS and DM2 were significantly older and had the highest BMI. All patients with CCS were on acetylsalicylic acid, and 95% of CCS patients were on high-dose statins. The absolute leukocyte and neutrophile count increased significantly in the control group during the OFTT in comparison to CCS subjects. There was a significant decrease of HDL and increase of triglycerides during the OFTT, however with no difference between groups. There was no difference in the change of platelet activity between all groups.

Conclusion

This study showed that OFTT leads to an increased postprandial inflammation response in healthy group compared to CCS ± DM2 while there was no change in lipid profile and platelet activity.

背景和目的：动脉粥样硬化的变化主要是在非禁食脂质的影响下发生的。到目前为止，餐后状态下的研究主要在健康受试者身上进行。这项探索性的横断面研究调查了餐后状态下不同心血管风险状况患者的脂质状况、炎症和血小板活化的变化。方法：研究人群包括66名具有不同心血管风险的患者：有慢性冠状动脉综合征（CCS）和2型糖尿病（DM2）病史的患者（n=20），无DM2病史的CCS患者（n=25），以及健康对照组（n=21）。在禁食状态期间以及标准化脂肪餐后3小时和5小时，使用标准化口服脂肪耐受测试（OFTT）（含90g脂肪的奶昔）评估脂质变量、血小板功能和炎症标志物。结果：CCS和DM2患者年龄明显较大，BMI最高。所有CCS患者均服用乙酰水杨酸，95%的CCS患者服用高剂量他汀类药物。与CCS受试者相比，对照组在OFTT期间的白细胞和中性粒细胞绝对计数显著增加。在OFTT期间，HDL显著降低，甘油三酯升高，但各组之间没有差异。各组间血小板活性变化无显著性差异。结论：与CCS±DM2相比，OFTT导致健康组餐后炎症反应增加，而脂质和血小板活性没有变化。

{"title":"The LIPL study: Postprandial lipid profile, inflammation, and platelet activity in patients with chronic coronary syndrome","authors":"Edita Pogran , Paul M. Haller , Claudia Wegberger , Maximilian Tscharre , Irena Vujasin , Christoph C. Kaufmann , Petra Dick , Bernhard Jäger , Johann Wojta , Kurt Huber","doi":"10.1016/j.athplu.2023.09.002","DOIUrl":"10.1016/j.athplu.2023.09.002","url":null,"abstract":"<div><h3>Background and aims</h3><p>It is suggested that the changes in atherosclerosis happen mainly under the influence of non-fasting lipids. To date, the studies in the postprandial state were primarily performed on healthy subjects. This exploratory, cross-sectional study investigates the change in lipid profile, inflammation, and platelet activation in patients with different cardiovascular risk profiles in the postprandial state.</p></div><div><h3>Methods</h3><p>The studied population consists of 66 patients with different cardiovascular risks: patients with a history of the chronic coronary syndrome (CCS) and diabetes mellitus type 2 (DM2) (n = 20), CCS without DM2 (n = 25), and a healthy control group (n = 21). Lipid variables and markers of platelet function and inflammation were assessed during the fasting state and three and 5 h after a standardized fat meal using a standardized oral fat tolerance test (OFTT), a milkshake with 90 g of fat.</p></div><div><h3>Results</h3><p>Patients with CCS and DM2 were significantly older and had the highest BMI. All patients with CCS were on acetylsalicylic acid, and 95% of CCS patients were on high-dose statins. The absolute leukocyte and neutrophile count increased significantly in the control group during the OFTT in comparison to CCS subjects. There was a significant decrease of HDL and increase of triglycerides during the OFTT, however with no difference between groups. There was no difference in the change of platelet activity between all groups.</p></div><div><h3>Conclusion</h3><p>This study showed that OFTT leads to an increased postprandial inflammation response in healthy group compared to CCS ± DM2 while there was no change in lipid profile and platelet activity.</p></div>","PeriodicalId":72324,"journal":{"name":"Atherosclerosis plus","volume":null,"pages":null},"PeriodicalIF":1.6,"publicationDate":"2023-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/9d/1e/main.PMC10550804.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41174900","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

High-density lipoprotein cholesterol and multiple myeloma: A systematic review and meta-analysis 高密度脂蛋白胆固醇与多发性骨髓瘤:一项系统综述和荟萃分析

IF 1.6

Atherosclerosis plus

Pub Date : 2023-09-21 DOI: 10.1016/j.athplu.2023.09.003

Anastasios Makris , Antonia Pagkali , Emmanouil Nikolousis , Theodosios D. Filippatos , Aris P. Agouridis

Background and aims

To systematically investigate all relevant evidence on the association between high-density lipoprotein cholesterol (HDL-C) and multiple myeloma (MM).

Methods

We searched PubMed and Cochrane library databases (up to 20 September 2022) for studies with evidence on HDL-C in patients with MM. A qualitative synthesis of published prospective and retrospective studies for the role of HDL-C and other lipid profile parameters in MM was performed. Additionally, a meta-analysis on HDL-C mean differences (MD) between MM cases and controls was performed.

Results

Fourteen studies (3 prospective, 11 retrospective) including 895 MM patients were eligible for this systematic review. Ten studies compared HDL-C levels in MM patients with healthy controls. In these 10 studies (n = 17,213), pooled analyses showed that MM patients had significantly lower HDL-C levels compared to healthy controls (MD: −13.07 mg/dl, 95% CI: −17.83, −8.32, p < 0.00001). Regarding secondary endpoints, total cholesterol (TC) (MD: −22.19 mg/dl, 95% CI: −39.08, −5.30) and apolipoprotein A-I (apoA-I) (−40.20 mg/dl, 95% CI: −55.00, −25.39) demonstrated significant decreases, while differences in low-density lipoprotein cholesterol (LDL-C) (MD: −11.33 mg/dl, 95% CI: −36.95, 14.30) and triglycerides (MD: 9.93 mg/dl, 95% CI: −3.40, 23.26) were not shown to be significant.

Conclusions

HDL-C, as well as TC and apoA-I, levels are significantly decreased in MM. Hence, lipid profile parameters should be taken into account when assessing such patients.

背景与目的系统研究高密度脂蛋白胆固醇（HDL-C）与多发性骨髓瘤（MM）之间关系的所有相关证据。方法我们检索PubMed和Cochrane图书馆数据库（截至2022年9月20日），寻找有证据表明MM患者HDL-C的研究。对已发表的HDL-C和其他脂质特征参数在MM中的作用的前瞻性和回顾性研究进行定性综合。此外，对MM病例和对照组之间的HDL-C平均差异（MD）进行了荟萃分析。结果14项研究（3项前瞻性研究，11项回顾性研究），包括895例MM患者，符合本系统综述的条件。10项研究比较了MM患者和健康对照组的HDL-C水平。在这10项研究中（n=17213），汇总分析显示，与健康对照组相比，MM患者的HDL-C水平显著较低（MD:−13.07 mg/dl，95%CI:−17.83，−8.32，p<；0.00001）。关于次要终点，总胆固醇（TC）（MD:−22.19 mg/dl，95%CI:−39.08，−5.30）和载脂蛋白A-I（apoA-I）（−40.20 mg/dl，95%CI:−55.00，−25.39）显著降低，而低密度脂蛋白胆固醇（LDL-C）（MD:−11.33 mg/dl，95%CI:−36.95，14.30）和甘油三酯（MD:9.93 mg/dl、95%CI:–3.40，23.26）的差异没有显著性。结论MM患者的HDL-C、TC和apoA-I水平显著降低。因此，在评估此类患者时应考虑血脂谱参数。

{"title":"High-density lipoprotein cholesterol and multiple myeloma: A systematic review and meta-analysis","authors":"Anastasios Makris , Antonia Pagkali , Emmanouil Nikolousis , Theodosios D. Filippatos , Aris P. Agouridis","doi":"10.1016/j.athplu.2023.09.003","DOIUrl":"10.1016/j.athplu.2023.09.003","url":null,"abstract":"<div><h3>Background and aims</h3><p>To systematically investigate all relevant evidence on the association between high-density lipoprotein cholesterol (HDL-C) and multiple myeloma (MM).</p></div><div><h3>Methods</h3><p>We searched PubMed and Cochrane library databases (up to 20 September 2022) for studies with evidence on HDL-C in patients with MM. A qualitative synthesis of published prospective and retrospective studies for the role of HDL-C and other lipid profile parameters in MM was performed. Additionally, a meta-analysis on HDL-C mean differences (MD) between MM cases and controls was performed.</p></div><div><h3>Results</h3><p>Fourteen studies (3 prospective, 11 retrospective) including 895 MM patients were eligible for this systematic review. Ten studies compared HDL-C levels in MM patients with healthy controls. In these 10 studies (n = 17,213), pooled analyses showed that MM patients had significantly lower HDL-C levels compared to healthy controls (MD: −13.07 mg/dl, 95% CI: −17.83, −8.32, p < 0.00001). Regarding secondary endpoints, total cholesterol (TC) (MD: −22.19 mg/dl, 95% CI: −39.08, −5.30) and apolipoprotein A-I (apoA-I) (−40.20 mg/dl, 95% CI: −55.00, −25.39) demonstrated significant decreases, while differences in low-density lipoprotein cholesterol (LDL-C) (MD: −11.33 mg/dl, 95% CI: −36.95, 14.30) and triglycerides (MD: 9.93 mg/dl, 95% CI: −3.40, 23.26) were not shown to be significant.</p></div><div><h3>Conclusions</h3><p>HDL-C, as well as TC and apoA-I, levels are significantly decreased in MM. Hence, lipid profile parameters should be taken into account when assessing such patients.</p></div>","PeriodicalId":72324,"journal":{"name":"Atherosclerosis plus","volume":null,"pages":null},"PeriodicalIF":1.6,"publicationDate":"2023-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10539640/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41175749","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

首页上一页

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Atherosclerosis plus

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀